A new clinical trial is evaluating selinexor, a non-JAK inhibitor, as a first-line therapy in myelofibrosis, with a JAK inhibitor added later only if needed. This innovative sequencing challenges the current, long-standing paradigm of initiating all treatments with a JAK inhibitor.

A proactive clinical practice is to refer all newly diagnosed myelofibrosis patients for a transplant consultation, irrespective of their initial risk score. This preemptive step helps overcome significant logistical delays in finding a suitable donor, which is particularly crucial for patients from diverse ethnic backgrounds where donor availability is limited.

Recent Phase 3 trials for novel myelofibrosis combinations (e.g., pelabrasib or selinexor with ruxolitinib) show a consistent pattern. They successfully reduce spleen volume but fail to demonstrate a statistically significant improvement in patient-reported symptom scores compared to ruxolitinib alone, questioning the link between these two endpoints.

The treatment paradigm for ITP is shifting towards early combination therapy. Recent clinical trials are investigating augmented first- and second-line regimens, such as combining dexamethasone with rituximab or romiplostim, to achieve more durable, treatment-free responses than monotherapy.

For myelofibrosis patients with profound splenomegaly but only moderate thrombocytopenia (platelets 50k-100k), fedratinib may be the best frontline option. It is arguably the most potent JAK inhibitor for spleen reduction and is approved for use in patients with platelet counts as low as 50,000.

Clinicians should avoid delaying myelofibrosis treatment, especially in asymptomatic patients with massive splenomegaly. Waiting can lead to a downward spiral of complications like thrombocytopenia, which limits future therapeutic options. The greater clinical error is inaction and waiting too long to intervene.

A critical challenge in myelofibrosis care is that the optimal time for a curative transplant is when patients feel well, often due to effective JAK inhibitor therapy. This feeling of well-being makes them reluctant to undergo the high-risk procedure. Waiting until they feel sick makes the transplant less likely to succeed.

A patient's risk score primarily determines their candidacy for a stem cell transplant. However, the decision to start a JAK inhibitor is driven by symptoms like splenomegaly and constitutional issues, regardless of the patient's formal risk status. This decouples two key treatment decisions.

For myelofibrosis patients with both anemia and splenomegaly, a practical approach is to start with ruxolitinib for its superior symptom control. If the subsequent anemia is not well-tolerated, switching to momelotinib allows for a more informed, personalized decision based on the patient's experience with both agents.